Recent studies confirm that endothelial dysfunction is an important pathogenetic mechanism in both atrial fibrillation and cancer-associated thromboses. It promotes inflammation, activation of coagulation and development of thrombosis, which requires the development of new therapeutic approaches to reduce the risk of thromboembolic complications (TEC) in such patients. The ongoing trials support the use of apixaban for the treatment of venous TEC in patients with active oncopathology in combination with atrial fibrillation, which confirms its efficacy and safety. This allows apixaban to be used both in outpatient settings and for long-term treatment with minimal risks of major bleeding, which is an important step in improving the quality of life of cancer patients.

Keywords: oncology, thrombosis, anticoagulants, atrial fibrillation